The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

N/AApproved For MarketingNCT00438789

Alexion Pharmaceuticals, Inc.

Overview

The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.

Study Type

EXPANDED_ACCESS

Conditions

Hemoglobinuria, Paroxysmal

Interventions

eculizumabDRUG

600mg IV every week and 900mg IV every 2 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PNH; * At least 18 years old * Avoid conception; and * Willing and able to give written informed consent Exclusion Criteria: * Active bacterial infection * Participation in any other drug trial * Pregnant breast feeding, or intending to conceive * Not vaccinated against N meningitidis

Locations (1)

Anthony Botti

Livingston, New Jersey, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.